In this article, we highlight ICER's dual role as a repressor of oncogenic pathways and a target of proteasomal degradation and show that the ubiquitin-resistant S35-41A-ICER mutant not only mitigates tumor progression but also prolongs survival in a brafV600E-driven melanoma context. The gene discussed is CREM; the disease is melanoma.